心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Lancet：阿格列汀不增加2型糖尿病心衰风险（EXAMINE 试验）

2015-03-31 沐晴 译 MedSci原创

阿格列汀2型糖尿病心衰
关注

先前有一项EXAMINE研究证明DPP-4抑制剂阿格列汀与安慰剂相比，在增加T2DM主要心血管事件风险中呈非劣性。而另一项报道称使用DPP-4抑制剂可能增加住院患者心衰风险，令人担忧。因此，近来有研究进行另一项EXAMINE评估阿格列汀对入院患者发生心衰的影响。 试验中，研究者将已接受糖尿病标准化和心血管疾病预防治疗的2型糖尿病合并ACS患者，随机分为阿格列汀或安慰剂治疗组。 预先设定的评价终

先前有一项EXAMINE研究证明DPP-4抑制剂阿格列汀与安慰剂相比，在增加T2DM主要心血管事件风险中呈非劣性。而另一项报道称使用DPP-4抑制剂可能增加住院患者心衰风险，令人担忧。因此，近来有研究进行另一项EXAMINE评估阿格列汀对入院患者发生心衰的影响。

试验中，研究者将已接受糖尿病标准化和心血管疾病预防治疗的2型糖尿病合并ACS患者，随机分为阿格列汀或安慰剂治疗组。

预先设定的评价终点——主要不良心脏事件（MACE）有全因死亡、非致死性的心肌梗死，非致死性的休克，因不稳定性心绞痛采取的紧急血流重建，以心衰入院。通过既往的心衰病史和BNP水平评估，药物导致的心脏事件和因心衰入院的因果关系。同时，还评估了从基础状态到加阿格列汀后6个月，NT-pro-BNP的水平。
 

 
研究中有5380名患者入组，随机给予阿格列汀(n=2701)或安慰剂(n=2679)治疗，随访中位数是533天（四分位数区间是280-751天）。结果发现有阿格列汀组有433名患者（16•0%）出现了主要不良心脏事件，而安慰剂组有441名患者(16•5%)出现了主要不良心脏，（HR 0•98, 95% CI 0•86-1•12)。因心衰入院是排名第一的心血管事件，在阿格列汀组有85(3•1%)名患者，安慰剂组79(2•9%)名患者， (HR 1•07, 95% CI 0•79-1•46)。结果显示，阿格列汀对总体的心血管死亡率和因心衰住院率没有影响(HR 1•00, 95% CI 0•82-1•21) 。阿格列汀组和安慰剂组中基础BNP水平并无差别， NT-pro-BNP水平显著下降，但是两组水平并无差别。

最后，研究者认为，对T2DM合并近期ACS患者，阿格列汀并不增加心衰发生的风险。

注释：非劣效性（non-inferiority）试验/等效性(equivalence)试验—显示非劣效性或等效性的设计，以阳性药物为对照，试验的目标是显示试验药物的疗效与某种已知的阳性药物“不差”或“相当”，分别称为非劣效性试验和等效性试验。

原始出处：

Zannad F1, Cannon CP2, Cushman WC3, Bakris GL4, Menon V5, Perez AT6, Fleck PR6, Mehta CR7, Kupfer S6, Wilson C6, Lam H6, White WB8; EXAMINE Investigators.Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.Lancet. 2015 Mar 9. pii: S0140-6736(14)62225-X. doi: 10.1016/S0140-6736(14)62225-X. [Epub ahead of print]

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2016-02-18 jiafufeng@yaho

    #EXAMINE#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-04 howi

    #Lancet#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-06-11 ljjj1053

    好好学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-11 x35042875

    AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-02 CRAZYDAFF

    意义

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-02 ms3994565386320060

    #心衰风险#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-02 lizhou0210

    #阿格列汀#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1785899, encodeId=a7251e8589970, content=<a href='/topic/show?id=5677e145e6' target=_blank style='color:#2F92EE;'>#EXAMINE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7145, encryptionId=5677e145e6, topicName=EXAMINE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Feb 18 21:33:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828044, encodeId=4f36182804456, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 04 18:33:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27097, encodeId=b0dc2e097bf, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:42:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20321, encodeId=65db20321dd, content=AKI对心衰临床治疗意义重大，但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:38:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19258, encodeId=5e9719258ce, content=意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Thu Apr 02 21:53:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389435, encodeId=9ca6138943500, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597013, encodeId=f97f159e013e1, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Apr 02 02:33:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19126, encodeId=2a8319126f4, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-03-31 cd90

    有意义

    0

相关资讯

ADA2013：阿格列汀与二甲双胍联用治疗糖尿病效果好

　　一项名为ENSURE（比较阿格列汀与格列吡嗪在与二甲双胍联用两年的疗效与安全性的持久性试验）的研究，近日在第73届美国糖尿病学会年会（ADA）上发布。 　　该研究历时2年，旨在获得有关阿格列汀在治疗II型糖尿病患者的疗效和安全性方面的新数据。ENDURE研究是一项多中心的随机双盲活性对照研究，由日本武田药品工业株式会社组织多国专家开展，用以评估阿格列汀和格列吡嗪在与二甲双胍联用时，其

NEJM：阿格列汀能安全用于T2DM患者合并心血管高危风险(EXAMINE研究）

　  对于T2DM患者合并心血管高危风险（15-90天内有急性心梗和不稳定性心绞痛住院患者），加用阿格列汀（alogliptin）或安慰剂治疗，发现alogliptin并不增加主要大血管事件，对于糖尿病合并心血管高危风险患者是安全的。这是EXAMINE研究的核心结果。结果将于ESC荷兰阿姆斯特丹当地时间9月2日上午11:18公布；NEJM 新英格兰杂志将同步于ESC期间发表。 原始出处

FDA批准阿格列汀3种不同制剂用于治疗2型糖尿病

2013年1月25日，美国食品与药物管理局（FDA）批准了选择性二肽基肽酶-Ⅳ（DPP-4）抑制剂阿格列汀（alogliptin）的3种制剂上市，用于改善成人2型糖尿病的血糖水平。这3种制剂分别为阿格列汀片、阿格列汀与盐酸二甲双胍固定剂量复合片剂和阿格列汀与吡格列酮复合片剂（商品名依次为Nesina、Kazano和Oseni）。FDA发布的公告显示，这3种药物不适用于1型糖尿病或糖尿病酮症酸中毒患